ALBERICI v. RECRO PHARMA, INC.

CourtDistrict Court, E.D. Pennsylvania
DecidedDecember 1, 2022
Docket2:18-cv-02279
StatusUnknown

This text of ALBERICI v. RECRO PHARMA, INC. (ALBERICI v. RECRO PHARMA, INC.) is published on Counsel Stack Legal Research, covering District Court, E.D. Pennsylvania primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
ALBERICI v. RECRO PHARMA, INC., (E.D. Pa. 2022).

Opinion

IN THE UNITED STATES DISTRICT COURT FOR THE EASTERN DISTRICT OF PENNSYLVANIA

JOHN ALBERICI, individually and on behalf of all others similarly situated, Plaintiffs,

v. CIVIL ACTION NO. 18-2279

RECRO PHARMA, INC., GERALDINE A. HENWOOD, STEWART MCCALLUM, and JOHN HARLOW, Defendants.

MEMORANDUM RE: MOTION FOR FINAL APPROVAL OF SETTLEMENT, PLAN FOR ALLOCATION, AWARD OF ATTORNEY’S FEES AND EXPENSES Baylson, J. December 1, 2022 I. Introduction The Court has considered the request of Lead Plaintiff, Recro Investor Group, for final approval of the settlement and award of counsel fees and expenses. The sequence of events in this case resembles the short life of a failed opera. With strong advance sales, the Director/Conductor of this Opera had been hard at work in preparation, with many hours spent, and was very much looking forward to the lead Soprano’s debut and success. However, after opening night’s overture, when Soprano took the stage, she couldn’t sing a note. The Conductor quickly realized that the Soprano on stage was different than the Soprano he heard at an audition, who was excellent. He had been deceived! What should he do? After a quick consultation with the orchestra, they agreed to stop the Opera and cancel the rest of the Opera’s performances. The audience was in an uproar and demanded a refund. The Conductor had to make a quick decision. Any money the Conductor gave back to the audience would be taken out of the wages due to the orchestra and “a success fee” for himself. How should the huge amount of advanced sales be allocated? The Conductor wanted to be fair to the orchestra members and the audiences, but also fair to everyone who had purchased tickets to a grand evening at the Opera. He also expected to receive

some money for himself for all of the work he had done without any compensation so far. This quandary presents itself in this case. I. BACKGROUND A. Procedural Background This case is a securities fraud lawsuit brought against Defendant Recro Pharma, Inc., a publicly traded specialty pharmaceutical company, and a few of Recro’s executive officers for violations of Sections 10b-5 and 20(a) of the Securities Exchange Act. A class action complaint was filed on May 31, 2018 by John Alberici, a Recro Investor Group member, on behalf of all similarly situated plaintiffs. The claims stem from Recro’s stock plunging more than 50% immediately after Recro informed its investors that the FDA had declined to approve Recro’s

experimental analgesic drug ‘meloxicam’ for sale and marketing in the U.S, which all occurred on May 24, 2018. The individuals who are members of the Lead Plaintiff representing the class, Recro Investor Group, declared in their respective affidavits their pre-announcement ownership of Recro shares totaling approximately $280,000 in value (all of which had apparently been procured within two months of the announcement, and for one member the day before the announcement) and alleged that Defendants’ violations of the securities laws resulted in losses of approximately $130,000 from the devaluation of their Recro shares. On July 30, 2018, Alberici filed a motion to appoint Pomerantz LLP as lead counsel and Kaskela Law LLC as liaison counsel for the class, which would be represented by the Recro Investor Group consisting of the individuals with “the largest financial interest in this litigation.” On October 5, 2018, the Court approved the appointments of counsel and class representative. An Amended Complaint was filed on December 11, 2018, and Defendants filed a Motion to Dismiss Amended Complaint on February 8, 2019. A hearing regarding the motion to dismiss was held on

June 26, 2019 and supplemental briefing was ordered by the Court due September 26, 2019. On November 12, 2019, the case was placed by order of the Court on the Civil Suspense Docket to allow the Court more time to resolve issues related to the motion to dismiss. On February 14, 2020, the Court ordered the case dismissed without prejudice based on Plaintiffs’ failure to plead a strong inference of scienter, as outlined in the Court’s 37-page opinion. See Alberici v. Recro Pharma, Inc., No. 18-2279, 2020 WL 806719 (E.D. Pa. Feb. 14, 2020). On April 24, 2020 Plaintiffs filed a Second Amended Complaint, and Defendants responded with a Motion to Dismiss Second Amended Complaint on June 18, 2020. After settlement talks again failed, the Court denied Defendants’ motion to dismiss on March 1, 2021 and a discovery schedule was set with a fact discovery deadline of March 15, 2022. See Alberici v. Recro Pharma, Inc., No. 18-2279, 2021

WL 798299 (E.D. Pa. Mar. 1, 2021). After several months of discovery Plaintiffs filed a motion for class certification on September 30, 2021, which became fully briefed once Plaintiffs filed their reply on January 6, 2022. The Court set an evidentiary hearing to deal with some factual issues, but Plaintiffs submitted a letter to the Court on March 24, 2022 stating that they had reached a settlement-in- principle with Defendants and the hearing was cancelled. Plaintiffs filed an unopposed motion for preliminary approval of the settlement and preliminary certification of a settlement class on May 10, 2022, which the Court conditionally granted. See May 12, 2022 Order (ECF No. 110). Plaintiffs then filed this Motion for Final Approval on September 21, 2022, along with a Notice of Non-Opposition in Support that they filed on October 19, 2022. The Court held a hearing on the Motion on October 26, 2022. At the hearing, class counsel informed the Court that the case had run into various problems, included a lying confidential witness. Class counsel argued that while paths to success in the litigation still existed, the discovery burden (class counsel estimated that

over 100,000 pages of discovery were produced) and litigation risks made settlement the most favorable option for the class. B. Final Approval Briefing In its briefing of this Motion, Lead Plaintiff seeks final approval of an all-cash settlement totaling $1,400,000. Lead Plaintiff relates that the settlement amount was achieved through arms- length negotiation overseen by a mediator and that the amount represents the amount of work that went into the “hard-fought” litigation. Lead Plaintiff argues that the settlement meets the requirements under Rule 23(e)(2) and under Third Circuit case law, notably the factors outlined in Girsh v. Jepson, 521 F.2d 153, 157 (3d Cir. 1975). Lead Plaintiff also relates in its Notice of Non- Opposition that 5,100 potential settlement class members were notified by either mail or email of

the proposed class action settlement and plan of allocation, and that no objections were received. From the settlement fund, Lead Plaintiff requests: (1) $467,600 in attorney’s fees which is one-third of the settlement amount, plus interest; (2) $424,488.55 plus interest in reimbursed litigation expenses, and (3) an award of $7,500 each to the three individual members of the Lead Plaintiff, Recro Investor Group. Class counsel calculated its lodestar at $4,258,916.75, which is magnitudes above the settlement amount, let alone the requested attorney’s fees. II. LEGAL STANDARD A. Approval of Settlement A district court may only approve a settlement of class action litigation if it is “fair, reasonable, and adequate.” Fed.R.Civ.P. 23(e)(1)(C). The Third Circuit has identified nine factors

to guide district courts in approving proposed class action settlements.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Abrams v. Lightolier Inc.
50 F.3d 1204 (Third Circuit, 1995)
In Re: Cendant Corporation Prides Litigation
243 F.3d 722 (Third Circuit, 2001)
Edwin Maldonado v. Feather O. Houstoun
256 F.3d 181 (Third Circuit, 2001)
In Re: Cendant Corporation Litigation
264 F.3d 201 (Third Circuit, 1992)
Dewey v. Volkswagen Aktiengesellschaft
681 F.3d 170 (Third Circuit, 2012)
In Re Baby Products Antitrust Litigation
708 F.3d 163 (Third Circuit, 2013)
In Re Insurance Brokerage Antitrust Litigation
579 F.3d 241 (Third Circuit, 2009)
In Re Corel Corp. Inc. Securities Litigation
293 F. Supp. 2d 484 (E.D. Pennsylvania, 2003)
Erie County Retirees Ass'n v. County of Erie, Pa.
192 F. Supp. 2d 369 (W.D. Pennsylvania, 2002)
Dewey v. Volkswagen of America
728 F. Supp. 2d 546 (D. New Jersey, 2010)
In Re AT & T Corp.
455 F.3d 160 (Third Circuit, 2006)
Altnor v. Preferred Freezer Services, Inc.
197 F. Supp. 3d 746 (E.D. Pennsylvania, 2016)
Brown v. Rita's Water Ice Franchise Co.
242 F. Supp. 3d 356 (E.D. Pennsylvania, 2017)
Sullivan v. DB Investments, Inc.
667 F.3d 273 (Third Circuit, 2011)
Chester Upland School District v. Pennsylvania
284 F.R.D. 305 (E.D. Pennsylvania, 2012)

Cite This Page — Counsel Stack

Bluebook (online)
ALBERICI v. RECRO PHARMA, INC., Counsel Stack Legal Research, https://law.counselstack.com/opinion/alberici-v-recro-pharma-inc-paed-2022.